Limits...
Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both.

Pattan V, Seth S, Jehangir W, Bhargava B, Maulik SK - J Clin Med Res (2015)

Bottom Line: Atorvastatin monotherapy significantly reduced plasma sICAM-1, but pioglitazone monotherapy did not produce any significant effect.Addition of pioglitazone in patients already receiving atorvastatin also significantly reduced plasma sICAM-1 level.However, there was no significant change in plasma hsCRP and sVCAM-1 levels in any of the groups after 12 weeks of therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.

ABSTRACT

Background: It was to study the effect of atorvastatin, pioglitazone and their combination on plasma levels of adhesion molecules in patients with hypertension or stable angina or both.

Methods: It was an open-label, randomized parallel-group study. Forty-five atorvastatin-naive patients with hypertension or stable angina or both, were randomized to receive either atorvastatin (19 patients; 10 mg OD for 12 weeks) or pioglitazone (26 patients; 30 mg OD for 12 weeks). Another group of 30 patients who were already on atorvastatin were put on add-on pioglitazone therapy (pioglitazone (15 mg OD) + atorvastatin (10 mg OD) for 12 weeks). Plasma high-sensitivity C-reactive protein (hsCRP), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) levels were measured at baseline and after 12 weeks of therapy.

Results: Atorvastatin monotherapy significantly reduced plasma sICAM-1, but pioglitazone monotherapy did not produce any significant effect. Addition of pioglitazone in patients already receiving atorvastatin also significantly reduced plasma sICAM-1 level. However, there was no significant change in plasma hsCRP and sVCAM-1 levels in any of the groups after 12 weeks of therapy.

Conclusion: There is therapeutic advantage of combining pioglitazone and atorvastatin on plasma sICAM-1 levels.

No MeSH data available.


Related in: MedlinePlus

Changes in plasma sICAM-1 levels after treatment (*P < 0.05). Group 1: atorvastatin; group 2: pioglitazone; group 3: atorvastatin + pioglitazone.
© Copyright Policy - open access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4471748&req=5

Figure 1: Changes in plasma sICAM-1 levels after treatment (*P < 0.05). Group 1: atorvastatin; group 2: pioglitazone; group 3: atorvastatin + pioglitazone.

Mentions: Addition of pioglitazone (15 mg/day) to patients already taking atorvastatin further reduced plasma levels of sICAM-1 (P = 0.004) (Fig. 1) from baseline. Atorvastatin monotherapy produced significant (P = 0.01) reduction in plasma levels of sICAM-1, but this was not seen not with pioglitazone monotherapy (P = 0.23). There was no significant (P > 0.05) difference in plasma sICAM-1 between patients receiving atorvastatin and patients receiving combination of atorvastatin and pioglitazone. When compared to baseline, there was no significant change (P > 0.05) in levels of sVCAM-1 (Fig. 2) and hsCRP (Fig. 3) levels in any of the study groups after 12 weeks of therapy (Table 3).


Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both.

Pattan V, Seth S, Jehangir W, Bhargava B, Maulik SK - J Clin Med Res (2015)

Changes in plasma sICAM-1 levels after treatment (*P < 0.05). Group 1: atorvastatin; group 2: pioglitazone; group 3: atorvastatin + pioglitazone.
© Copyright Policy - open access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4471748&req=5

Figure 1: Changes in plasma sICAM-1 levels after treatment (*P < 0.05). Group 1: atorvastatin; group 2: pioglitazone; group 3: atorvastatin + pioglitazone.
Mentions: Addition of pioglitazone (15 mg/day) to patients already taking atorvastatin further reduced plasma levels of sICAM-1 (P = 0.004) (Fig. 1) from baseline. Atorvastatin monotherapy produced significant (P = 0.01) reduction in plasma levels of sICAM-1, but this was not seen not with pioglitazone monotherapy (P = 0.23). There was no significant (P > 0.05) difference in plasma sICAM-1 between patients receiving atorvastatin and patients receiving combination of atorvastatin and pioglitazone. When compared to baseline, there was no significant change (P > 0.05) in levels of sVCAM-1 (Fig. 2) and hsCRP (Fig. 3) levels in any of the study groups after 12 weeks of therapy (Table 3).

Bottom Line: Atorvastatin monotherapy significantly reduced plasma sICAM-1, but pioglitazone monotherapy did not produce any significant effect.Addition of pioglitazone in patients already receiving atorvastatin also significantly reduced plasma sICAM-1 level.However, there was no significant change in plasma hsCRP and sVCAM-1 levels in any of the groups after 12 weeks of therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.

ABSTRACT

Background: It was to study the effect of atorvastatin, pioglitazone and their combination on plasma levels of adhesion molecules in patients with hypertension or stable angina or both.

Methods: It was an open-label, randomized parallel-group study. Forty-five atorvastatin-naive patients with hypertension or stable angina or both, were randomized to receive either atorvastatin (19 patients; 10 mg OD for 12 weeks) or pioglitazone (26 patients; 30 mg OD for 12 weeks). Another group of 30 patients who were already on atorvastatin were put on add-on pioglitazone therapy (pioglitazone (15 mg OD) + atorvastatin (10 mg OD) for 12 weeks). Plasma high-sensitivity C-reactive protein (hsCRP), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) levels were measured at baseline and after 12 weeks of therapy.

Results: Atorvastatin monotherapy significantly reduced plasma sICAM-1, but pioglitazone monotherapy did not produce any significant effect. Addition of pioglitazone in patients already receiving atorvastatin also significantly reduced plasma sICAM-1 level. However, there was no significant change in plasma hsCRP and sVCAM-1 levels in any of the groups after 12 weeks of therapy.

Conclusion: There is therapeutic advantage of combining pioglitazone and atorvastatin on plasma sICAM-1 levels.

No MeSH data available.


Related in: MedlinePlus